How 'open' will Big Pharma get to treat R&D ills?

It seems like every month Big Pharma companies roll out a new partnership or initiative to ease their pipeline pains, which include skyrocketing costs of drug development and historically unproductive research. FiercePharma Editor Tracy Staton took a dive into the world of "open" collaboration in the drug business, and how a spate of efforts among drugmakers to join forces on a range of research woes has captivated the industry. The big question is, will these efforts work? Download